BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macek Jílková Z, Seigneurin A, Coppard C, Ouaguia L, Aspord C, Marche PN, Leroy V, Decaens T. Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals. Cancers (Basel) 2020;12:E3820. [PMID: 33352852 DOI: 10.3390/cancers12123820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ali ME, Halby HM, Ali MY, Hassan EA, El-Mokhtar MA, Sayed IM, Thabet MM, Fouad M, El-Ashmawy AM, Mahran ZG. Role of Serum Vitamin D, Interleukin 13, and microRNA-135a in Hepatocellular Carcinoma and Treatment Failure in Egyptian HCV-Infected Patients Receiving Direct Antiviral Agents. Viruses 2021;13:2008. [PMID: 34696438 DOI: 10.3390/v13102008] [Reference Citation Analysis]
2 Weigand K, Peschel G, Grimm J, Luu K, Schacherer D, Wiest R, Müller M, Schwarz H, Buechler C. Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiology. Eur J Immunol 2021. [PMID: 34914098 DOI: 10.1002/eji.202149488] [Reference Citation Analysis]
3 Macek Jilkova Z, Saleem K, Afzal S, Decaens T. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. Livers 2021;1:313-21. [DOI: 10.3390/livers1040024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li CM, Chen Z. Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation. Front Cell Dev Biol 2021;9:664305. [PMID: 34235145 DOI: 10.3389/fcell.2021.664305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107 [DOI: 10.3748/wjg.v28.i1.96] [Reference Citation Analysis]